In our study, we created numerous independent AU-15330-resistant prostate cancer lines and identified two classes of resistance mechanisms: one mechanism by which mutations occur in the drug binding site of SMARCA4 and another mechanism by which ABCB1 is overexpressed. Here, SMARCA4 is linked to prostate carcinoma.